glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results agonists in patients with chronic disease and either overweight or obesity Kidney and Cardiovascular Outcomes Among

The once-daily oral semaglutide addresses a critical challenge in obesity care: long-term adherence

Data Availability Statement No new data were created or analyzed in this study.

doi: 10.2337/dc19-0749 [DOI] [PubMed] [Google Scholar] 222

Glucagon-like peptide-1 (GLP-1) is a hormone produced in the body that plays a key role in regulating your blood sugar levels

95% CI 1.6, 0.39), phentermine/topiramate (WMD: 0.7

Finally, individuals with a history of heart failure, ischaemic heart disease, unstable angina, myocardial infarction, aortic aneurysm or dissection, stroke (ischaemic or haemorrhagic stroke), cerebral infarction, transient ischaemic attack, carotid intervention or surgery, coronary stenting, percutaneous coronary intervention (PCI) or coronary artery bypass before inclusion to the cohort or prior to the index event were also excluded